Brian Baumann is a radiation oncology resident physician at the Hospital of the University of Pennsylvania. He completed his undergraduate studies at Princeton University and his medical degree at the University of Pennsylvania, where he was the recipient of an NIH T-32 training grant funding pre-clinical research on novel therapeutics for glioblastoma multiforme.
His research with John Christodouleas in the field of bladder cancer demonstrated the significant problem of local-regional failure after radical cystectomy for patients with locally advanced disease and provided the underpinning for the NRG-GU001 cooperative-group trial of postoperative radiation therapy vs. observation as well as similar cooperative group trials opening in the UK (NCRI) and France (GETUG-AFU) as well as Tata Memorial Hospital in India. The selection criteria for these trials was based on the externally validated risk stratification that he developed to identify patients at highest risk for local failure; the target volumes were derived from his patterns of failure analysis; and the decision to mandate intensity-modulated radiation therapy (IMRT) for the NRG trial was based on his dosimetric comparison that found lower bowel and rectal dose with IMRT compared to 3D-conformal radiation. He was the lead-author for an international collaboration of 24 radiation oncologists and urologists that developed consensus contouring guidelines for adjuvant radiation therapy for bladder cancer.
In addition to his work on bladder cancer, he is interested in comparative effectiveness research comparing photon vs. proton radiation therapy.